CRSP
CRISPR Therapeutics AG · Healthcare · Biotechnology
动量输入(同类管理人): 持有人广度 0.0% · 股份流向 +4.1% · 净新建仓位 0.0% · 公式
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q2 2025
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 22.66K | $1.16M | n/a | −1 |
| Q2 2026 | 114 | +6 | 51.82M | $2.83B | +10 | −5 |
| Q1 2026 | 112 | -2 | 52.07M | $2.48B | +5 | −8 |
| Q4 2025 | 114 | 0 | 52.74M | $2.77B | +1 | n/a |
| Q3 2025 | 15 | 0 | 31.49M | $2.04B | +1 | −2 |
| Q2 2025 | 13 | 0 | 27.95M | $1.36B | +1 | −1 |
| Q1 2025 | 10 | +2 | 16.56M | $563.38M | +2 | n/a |
| Q4 2024 | 8 | -2 | 14.13M | $556.07M | n/a | −2 |
| Q3 2024 | 9 | -1 | 10.14M | $476.58M | n/a | −1 |
| Q2 2024 | 10 | n/a | 10.63M | $574.07M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 10.18M | +0.2% | $495.28M | 3.6% | ▲ Add | 5 | SEC ↗ |
| 2 | BlackRock ✦ (被动) | 6.07M | n/a | $295.07M | 0.0% | n/c | 1 | SEC ↗ ×15 |
| 3 | State Street Global Advisors ✦ (被动) | 3.27M | +35.6% | $159.08M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | The Vanguard Group ✦ (被动) | 2.30M | n/a | $111.78M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 5 | Geode Capital Management ✦ (被动) | 2.07M | +98.1% | $100.79M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | Fidelity (FMR) ✦ | 1.93M | n/a | $93.83M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 7 | Two Sigma Investments ✦ | 1.55M | +30.0% | $75.20M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 8 | Norges Bank ✦ (被动) | 406.49K | -10.9% | $19.77M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 9 | Millennium Management ✦ | 70.09K | -88.0% | $3.41M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 66.37K | +142.5% | $3.23M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 21.61K | -14.6% | $1.05M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 12 | Citadel Advisors ✦ | 18.88K | -92.7% | $918,226 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Gotham Asset Management ✦ | 5.10K | 新增 | $248,113 | 0.0% | New | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例,即持仓信心指标。✦ = 精选管理人。
新增买入方
| Gotham Asset Management | $248,113 | 0.0% |
已清仓
| Marshall Wace | $13.38M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 488 持有人, 76.60M 股份, $3.47B 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券:基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer, Director · 47.84K 股 · $2.38M
Director · 14.51K 股 · $720,373
Officer, Director · 4.10K 股 · $201,867
Officer · 1.04K 股 · $51,230
Officer · 1.99K 股 · $119,481
Officer · 10.40K 股 · $626,460
Director · 13.68K 股 · $780,935
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论